Home Overview Research Programs Shared Facilities News & Outreach Technology Transfer Employment About PHRI

 
Scientific Overview Research Interest Summary Principal Investigators    Yuri Bushkin, Ph.D.
   Theresa Chang, Ph.D.
   Neeraj Chauhan, Ph.D.
   Véronique Dartois, Ph.D.
   Thomas Dick, Ph.D.
   Karl Drlica, Ph.D.
   David Dubnau, Ph.D.
   Eliseo A. Eugenin, Ph.D.
   Marila Gennaro, M.D.
   Gilla Kaplan, Ph.D.
   Fred Kramer, Ph.D.
   Barry Kreiswirth, Ph.D.
   Min Lu, Ph.D.
   Leonard Mindich, Ph.D.
   Arkady Mustaev, Ph.D.
   Jyothi Nagajyothi, Ph.D.
   David Perlin, Ph.D.
   Richard Pine, Ph.D.
   Abraham Pinter, Ph.D.
   Marcela Rodriguez, Ph.D.
   Selvakumar Subbian, Ph.D.
   Sanjay Tyagi, Ph.D.
   Christopher Vinnard, M.D.
   Chaoyang Xue, Ph.D.
   Xilin Zhao, Ph.D.

   Research Faculty
   Liang Chen, Ph.D.
   Eugenie Dubnau, Ph.D.
   Jeanette Hahn, Ph.D.
   Salvatore Marras, Ph.D.
   Lanbo Shi, Ph.D.
   Yanan Zhao, Ph.D.

Emeritus Faculty Recent Publications
 
Thomas Dick, Ph.D.

Research Summary  |  Selected Publications  |  C.V.
 

Public Health Research Institute Center
Associate Professor & Director of Antimicrobial Drug Discovery
New Jersey Medical School - Rutgers, The State University of New Jersey
225 Warren Street
Newark, New Jersey 07103

Phone: (973) 854-3220
e-mail: td367@njms.rutgers.edu


Research Summary

We are living in the perfect storm: Resistance of bacteria against antibiotics is increasing and the drug discovery pipelines in industry are empty. There is an urgent medical need for the discovery and development of new antibacterials. This lab is interested in understanding the molecular mechanisms of antibiotic resistance and in exploiting this knowledge for the discovery of new antibacterials. A major focus is the identification of novel lead – target couples for lead optimization campaigns with the objective of delivering preclinical development compounds. The disease area of interest are mycobacterial infections: Tuberculosis (TB) and lung disease caused by Non-Tuberculous Mycobacteria (NTM).




Selected Publications


Yee M, Gopal P, Dick T (2017) Missense Mutations in the Unfoldase ClpC1 of the Caseinolytic Protease Complex Are Associated with Pyrazinamide Resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 61. PMI: 27872068

Yang T, Moreira W, Nyantakyi SA, Chen H, Aziz DB, Go ML, Dick T (2017) Amphiphilic Indole Derivatives as Antimycobacterial Agents: Structure-Activity Relationships and Membrane Targeting Properties. J Med Chem. PMI: 28290692

Yamada Y, Dick T (2017) Mycobacterial Caseinolytic Protease Gene Regulator ClgR Is a Substrate of Caseinolytic Protease. mSphere 2. PMI: 28317028

Moreira W, Santhanakrishnan S, Ngan GJ, Low CB, Sangthongpitag K, Poulsen A, Dymock BW, Dick T (2017) Towards Selective Mycobacterial ClpP1P2 Inhibitors with Reduced Activity Against the Human Proteasome. Antimicrob Agents Chemother. PMI: 28193668

Gopal P, Tasneen R, Yee M, Lanoix JP, Sarathy J, Rasic G, Li L, Dartois V, Nuermberger E, Dick T (2017) In Vivo-Selected Pyrazinoic Acid-Resistant Mycobacterium tuberculosis Strains Harbor Missense Mutations in the Aspartate Decarboxylase PanD and the Unfoldase ClpC1. ACS Infect Dis. PMI: 28271875

Wu ML, Gengenbacher M, Dick T (2016) Mild Nutrient Starvation Triggers the Development of a Small-Cell Survival Morphotype in Mycobacteria. Front Microbiol 7: 947. PMI: 27379076

Wu ML, Gengenbacher M, Chung JC, Chen SL, Mollenkopf HJ, Kaufmann SH, Dick T (2016) Developmental transcriptome of resting cell formation in Mycobacterium smegmatis. BMC Genomics 17: 837. PMI: 27784279

Wu ML, Chan CL, Dick T (2016) Rel Is Required for Morphogenesis of Resting Cells in Mycobacterium smegmatis. Front Microbiol 7: 1390. PMI: 27630635

Mukherjee D, Zou H, Liu S, Beuerman R, Dick T (2016) Membrane-targeting AM-0016 kills mycobacterial persisters and shows low propensity for resistance development. Future Microbiol 11: 643-650. PMI: 27158932

Moreira W, Lim JJ, Yeo SY, Ramanujulu PM, Dymock BW, Dick T (2016) Fragment-Based Whole Cell Screen Delivers Hits against M. tuberculosis and Non-tuberculous Mycobacteria. Front Microbiol 7: 1392. PMI: 27656168

Moreira W, Aziz DB, Dick T (2016) Boromycin Kills Mycobacterial Persisters without Detectable Resistance. Front Microbiol 7: 199. PMI: 26941723

Kundu S, Biukovic G, Gruber G, Dick T (2016) Bedaquiline Targets the epsilon Subunit of Mycobacterial F-ATP Synthase. Antimicrob Agents Chemother 60: 6977-6979. PMI: 27620476

Koh JJ, Zou H, Mukherjee D, Lin S, Lim F, Tan JK, Tan DZ, Stocker BL, Timmer MS, Corkran HM, Lakshminarayanan R, Tan DT, Cao D, Beuerman RW, Dick T, Liu S (2016) Amphiphilic xanthones as a potent chemical entity of anti-mycobacterial agents with membrane-targeting properties. Eur J Med Chem 123: 684-703. PMI: 27517813

Hotra A, Suter M, Biukovic G, Ragunathan P, Kundu S, Dick T, Gruber G (2016) Deletion of a unique loop in the mycobacterial F-ATP synthase gamma subunit sheds light on its inhibitory role in ATP hydrolysis-driven H(+) pumping. FEBS J 283: 1947-1961. PMI: 26996828

Gopal P, Yee M, Sarathy J, Low JL, Sarathy JP, Kaya F, Dartois V, Gengenbacher M, Dick T (2016) Pyrazinamide Resistance Is Caused by Two Distinct Mechanisms: Prevention of Coenzyme A Depletion and Loss of Virulence Factor Synthesis. ACS Infect Dis 2: 616-626. PMI: 27759369

New Anti-Tubercular Compounds Targeting F-ATP Synthase. G. Grueber, R.W. Bates; A. Horta; T. Dick. Singapore patent application No.: 10201701210T; February 15, 2017.

Bortezomib As An Inhibitor Of Mycobacterial Caseinolytic Protease For Treatment Of Tuberculosis. T. Dick, W. Moreira, E. Rubin, R. Raju and B. Chia. International Application No.: PCT/US20160/16658; February 4, 2016.

New Dipeptidyl Boronates As Inhibitors Of Mycobacterial Caseinolytic Protease For The Treatment Of Tuberculosis. B Dymock, A Poulsen, T Dick, W Moreira, S Santhanakrishnan. Singapore application No.: 10201609299R; November 7, 2016.






C.V.


Dr Dick has 20 years of experience in mycobacteriology, antibacterial drug discovery and R and D program management. His research focuses on Non-Tuberculous Mycobacteria (NTM) infections and Tuberculosis (TB). Since March 2017 he is Director of Antimicrobial Drug Discovery and Associate Professor at the Public Health Research Institute (PHRI) and the Department of Medicine, New Jersey Medical School, Rutgers University. Dr Dick holds a Toh Chin Chye Visiting Professorship at the Department of Microbiology and Immunology, School of Medicine, National University of Singapore where he manages the TB drug discovery project portfolio of the School’s SPRINT-TB tuberculosis program which he co-founded in 2014. Prior to his current appointments he served 5 years as Director of the BSL3 Core Facility and Associate Professor at the National University of Singapore. Before he joined the National University Dr Dick worked for eight years in the pharmaceutical industry where he established and led the TB disease area at the Novartis Institute for Tropical Diseases, Singapore. He managed the discovery portfolio from target identification to preclinical development, and represented the industry partner in the Gates- and Wellcome-funded Grand Challenges in Global Health 11 consortium. To facilitate translational research he created a joint clinical research operation between Novartis, the Eijkman Institute and Hasanuddin University in Indonesia. Dr Dick completed his post-doctoral fellowship at the Institute of Molecular and Cell Biology in Singapore, where he became principal investigator heading the Mycobacterium Biology Laboratory. He studied biochemistry, genetics and microbiology at the University of Heidelberg where he obtained his PhD in molecular bacteriology.



 
     Copyright © 2017 All rights reserved.   PHRI at ICPH 225 Warren St. Newark, NJ 07103-3535 TEL 973 854 3100, FAX 973 854 3101